50

Phosphodiesterase inhibitors

Embed Size (px)

Citation preview

Page 1: Phosphodiesterase inhibitors
Page 2: Phosphodiesterase inhibitors
Page 3: Phosphodiesterase inhibitors

• The cyclic nucleotide phosphodiesterases degrade the phosphodiester bond in the second messenger cAMP and cGMP.

• PDEs are therefore important regulators of signal transduction mediated by these second messenger molecules.

• When referring to phosphodiesterases we usually refers to cyclic nucleotide phosphodiesterases which have great clinical implications.

• PDE family: 11 isoenzymes families (PDE 1-PDE 11) with over 50 isoforms

Page 4: Phosphodiesterase inhibitors
Page 5: Phosphodiesterase inhibitors
Page 6: Phosphodiesterase inhibitors
Page 7: Phosphodiesterase inhibitors
Page 8: Phosphodiesterase inhibitors
Page 9: Phosphodiesterase inhibitors
Page 10: Phosphodiesterase inhibitors

MAIN TISSUE LOCALIZATIONPDE

Brain, heart, vascular smooth muscle1

Adrenal cortex, brain, heart, corpus cavernosum2

Heart, corpus cavernosum, vascular smooth muscle, platelets, liver pancreas 3

Lung, mast cells, vascular smooth muscle4

Corpus cavernosum, lung, vascular smooth muscle, platelets, brain, esophagus5

Retina6

Skeletal muscle, T cells7

Testis, thyroid8

Broadly expressed, not well characterized9

Brain, testes10

Skeletal muscle, prostate, liver, kidney, pituitary, testis11

Page 11: Phosphodiesterase inhibitors
Page 12: Phosphodiesterase inhibitors

• Drugs that block subtypes of the enzyme phosphodiesterase (PDE).

• Therefore preventing the inactivation of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).

• They are classified into non-selective PDE inhibitors and selective PDE.

Page 13: Phosphodiesterase inhibitors

A) Nonselective phosphodiesterase inhibitors

Page 14: Phosphodiesterase inhibitors
Page 15: Phosphodiesterase inhibitors

B) Selective phosphodiesterase inhibitors

Page 16: Phosphodiesterase inhibitors

PDE4 selective inhibitors

• Mesembrine, Rolipram, Ibudilast, Piclamilast, Luteolin, Drotaverine.

PDE5 Inhibitors

• Sildenafil, Tadalafil, Vardenafil (10 times more potent than sildenafil) Udenafil , Avanafil, Lodenafil

Page 17: Phosphodiesterase inhibitors
Page 18: Phosphodiesterase inhibitors

Adverse drug reaction Proposed Mechanism

Nausea, Vomitting PDE 3 inhibition

Headache PDE 3 inhibition

Gatric Discomfort PDE 3 inhibition

Diuresis Adenosine antagonism

Cardiac Arrhythmias PDE 3 inhibition

Seizures Adenosine antagonism

Page 19: Phosphodiesterase inhibitors
Page 20: Phosphodiesterase inhibitors
Page 21: Phosphodiesterase inhibitors
Page 22: Phosphodiesterase inhibitors
Page 23: Phosphodiesterase inhibitors
Page 24: Phosphodiesterase inhibitors
Page 25: Phosphodiesterase inhibitors
Page 26: Phosphodiesterase inhibitors

Approved PDE3 inhibitors include the following:

• Amrinone

• Cilostazol

• Milrinone

• Enoximone

• Also referred as nonglycoside nonsympathomimetic ionotropic agents.

• Positive ionotropic on heart, vasodilatation of vessels.

Page 27: Phosphodiesterase inhibitors
Page 28: Phosphodiesterase inhibitors
Page 29: Phosphodiesterase inhibitors
Page 30: Phosphodiesterase inhibitors
Page 31: Phosphodiesterase inhibitors
Page 34: Phosphodiesterase inhibitors
Page 35: Phosphodiesterase inhibitors

• PDE5 has only one subtype, PDE5A, of which there are 4 isoforms in humans called PDE5A1-4.

• PDE5 enzyme is specific for cGMP which means it only hydrolyzes cGMP but not cAMP, the selectivity is mediated through network of hydrogen bonding which is favorable for cGMP but unfavorable for cAMP in PDE5.

• PDE5 is responsible for the degradation of cGMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis, which leads to erectile dysfunction (ED).

Page 36: Phosphodiesterase inhibitors
Page 37: Phosphodiesterase inhibitors

Cyclic GMP in turn activates a

specific protein kinase which

results in the opening of the

potassium channels and

hyperpolarization and causes

sequestration of intracellular

calcium and blocks calcium

influx. As a result of this drop in

cytosolic calcium, smooth

muscle relaxation occurs leading

to erection.

Page 38: Phosphodiesterase inhibitors

• PDE-5 inhibitors do not increase the nitric oxide level, but

they potentiate the nitric oxide effect to stimulate

erection.

• Without sexual arousal, these inhibitors are ineffective

Page 39: Phosphodiesterase inhibitors
Page 40: Phosphodiesterase inhibitors
Page 41: Phosphodiesterase inhibitors
Page 42: Phosphodiesterase inhibitors
Page 43: Phosphodiesterase inhibitors
Page 44: Phosphodiesterase inhibitors
Page 45: Phosphodiesterase inhibitors
Page 46: Phosphodiesterase inhibitors
Page 47: Phosphodiesterase inhibitors
Page 48: Phosphodiesterase inhibitors
Page 49: Phosphodiesterase inhibitors
Page 50: Phosphodiesterase inhibitors